Cosmo Pharmaceuticals N.V. News Releases

Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant

Wed, 15 Apr 2026 01:07:00 -0400

Ad hoc announcement pursuant to Art. 53 LR Long-term safety profile comparable to vehicle supports suitability for chronic use in a lifelong condition. Patients who remained on continuous Clascoterone treatment continued to gain hair through Month 12. In contrast, patients who switched to the placebo from Month 7 onwards experienced a reduction in treatment gains, demonstrating the importance of ongoing therapy. NDA and MAA preparations underway,...

Voting Results of Cosmo's 2026 AGM

Fri, 10 Apr 2026 09:16:00 -0400

Dublin, Ireland--(Newsfile Corp. - April 10, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting (AGM). A total of 10,354,065 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders. These shares make up 59.02% of the total outstanding ordinary shares in the share capital of Cosmo as of the record date. ...

Cosmo Highlights Leadership in Real Time Medical AI at NVIDIA GTC 2026

Mon, 16 Mar 2026 02:09:00 -0400

Dublin, Ireland--(Newsfile Corp. - March 16, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its participation at NVIDIA GTC 2026, the world’s leading conference for artificial intelligence (AI) and accelerated computing, taking place in San Jose (CA), USA, from March 16 to March 19. At the conference, Cosmo will present a technical session titled “Engineering Medical Grade Platforms for Real Time AI”, highlighting the Company’s...

Cosmo Presents Agenda for AGM 2026

Thu, 12 Mar 2026 01:58:00 -0400

Dublin, Ireland--(Newsfile Corp. - March 12, 2026) - Cosmo Pharmaceuticals N.V. (“Cosmo”) is pleased to announce the convening of its upcoming Ordinary Annual General Meeting of Shareholders (AGM) to be held on 10 April 2026 in Amsterdam. The agenda includes, among others, the following discussion and voting items: Report of the Board of Directors on the business year 2025 and the ESG achievements Appropriation of the Full-Year 2025 results ...

Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework

Mon, 09 Mar 2026 02:00:00 -0400

Ad hoc announcement pursuant to Art. 53 LR Full Year 2025 revenue of €104.2 million, in line with guidance, with 85% recurring revenues Recurring revenues of €88.1 million, +15% year-over-year, reflecting structural business transformation EBITDA of €9.5 million, exceeding the upper end of guidance Cash, equivalents and investments of €128.3 million as of December 31, 2025; no financial debt Proposed...

Cosmo Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus

Thu, 05 Mar 2026 01:00:00 -0500

Dublin, Ireland--(Newsfile Corp. - March 5, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an artificial intelligence (AI)-based computer-aided detection (CADe) system for the identification of early neoplasia in Barrett’s esophagus. The collaboration represents an important step in expanding the clinical...

Cosmo to Participate in Upcoming Investor Conferences

Wed, 18 Feb 2026 01:01:00 -0500

Dublin, Ireland--(Newsfile Corp. - February 18, 2026) - Cosmo Pharmaceuticals N.V. (“Cosmo”) is pleased to announce its participation in the following upcoming investor conferences: UBS European Healthcare Conference 2026 London, United Kingdom 4 March 2026 Svetlana Sigalova, Chief Financial Officer, will participate in one-on-one meetings with investors. Jefferies Biotech Summit 2026 Miami, United States 11...

Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares

Tue, 03 Feb 2026 01:10:00 -0500

Dublin, Ireland--(Newsfile Corp. - February 3, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the successful completion of a private placement of 937,086 treasury shares. The shares were placed with Capital Group’s SMALLCAP World Fund. The placement is equivalent to approximately 5.3% of Cosmo’s outstanding shares, subject to regulatory disclosure. The placement was executed using existing treasury shares and therefore does not...

Invitation to Cosmo's Full Year 2025 Financial Results Webcast on 9 March 2026

Wed, 28 Jan 2026 01:24:00 -0500

Dublin, Ireland--(Newsfile Corp. - January 28, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Full-Year 2025 results on Monday, 9 March 2026 at 7:00 am CET. Live conference call and audio webcast presentation: Cosmo invites investors, financial analysts and business/life sciences journalists to a live webcast presentation which will follow on the same day at 10:00 am CET. ...

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Mon, 12 Jan 2026 01:02:00 -0500

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in Cosmo’s Vision 2030, strengthening the Company’s foundations for scalable, innovation-driven growth across AI-enabled MedTech and pharma. Financial Highlights: High quality growth: €104 million revenue at guidance midpoint (€102 to €107 million) with recurring revenues representing the majority of sales and accelerating year over year ...